Minerva Neurosciences Inc. (NASDAQ:NERV) shares dropped 3.6% during mid-day trading on Thursday . The company traded as low as $10.17 and last traded at $10.25, with a volume of 150,662 shares trading hands. The stock had previously closed at $10.63.

A number of research analysts recently weighed in on NERV shares. Jefferies Group restated a “buy” rating and issued a $17.00 price objective on shares of Minerva Neurosciences in a research report on Wednesday, June 8th. Zacks Investment Research downgraded Minerva Neurosciences from a “buy” rating to a “sell” rating in a research report on Wednesday, June 1st. Finally, JMP Securities upped their price objective on Minerva Neurosciences from $10.00 to $17.00 in a research report on Thursday, May 26th.

The company’s 50-day moving average price is $10.87 and its 200 day moving average price is $6.94. The firm’s market capitalization is $292.27 million.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. On average, analysts forecast that Minerva Neurosciences Inc. will post ($1.05) EPS for the current fiscal year.

In other news, Director David Kupfer bought 55,635 shares of the business’s stock in a transaction that occurred on Tuesday, June 21st. The stock was acquired at an average cost of $10.84 per share, for a total transaction of $603,083.40. Following the purchase, the director now owns 209,188 shares of the company’s stock, valued at approximately $2,267,597.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson’s disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.